SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (1951)3/28/2002 7:34:10 AM
From: biostruggle  Read Replies (1) of 10345
 
Another failure from Elan.

Extremely disappointing.

UCB is a sub-optimal partner. It isn't a household name and doesn't have the necessary muscle to penetrate this competitive market," said Nick Staples, analyst at West LB Panmure.

He said UCB had a primary care sales force of around 475 in the United States, compared with more than 3,000 for a major player.

"This reaffirms our view that Frova will be a niche product," Staples added, forecasting annual sales of $100 million by 2006.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News